Counting Rate Characteristics and Image Distortion in Preclinical PET Imaging During Radiopharmaceutical Therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27469357.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PET may provide important information on the response during radiopharmaceutical therapy (RPT). Emission of radiation from the RPT radionuclide may disturb coincidence detection and impair image resolution. In this study, we tested the feasibility of performing intratherapeutic PET on 3 preclinical PET systems. Using <sup>22</sup>Na point sources and phantoms filled with <sup>18</sup>F, as well as a phantom filled with either <sup>99m</sup>Tc or <sup>177</sup>Lu, we evaluated the coincidence counting rate and spatial resolution when both a PET and a therapeutic radionuclide were in the PET system. Because <sup>99m</sup>Tc has a suitable half-life and is easy obtainable, we used it as a substitute for a generic therapeutic radionuclide. High activities of <sup>99m</sup>Tc deteriorated the coincidence counting rate from the <sup>18</sup>F-filled phantom and the <sup>22</sup>Na point source on all 3 systems. The counting rate could be corrected to a high degree on one of the systems by its dead-time correction. Spatial resolution was degraded at high <sup>99m</sup>Tc activities for all systems. On one of the systems, <sup>177</sup>Lu increased the coincidence counting rate and slightly affected the spatial resolution. The results for high <sup>177</sup>Lu activities were similar to those for <sup>99m</sup>Tc. Intratherapeutic imaging might be a feasible method of studying the response to RPT. However, some sensitive preclinical PET systems, unable to handle high counting rates, will have count losses and may also introduce image artifacts.
Medical subject headings
- Positron-Emission Tomography
- Radiopharmaceuticals